Tesamorelin Dosage Calculator
Work out your tesamorelin reconstitution concentration, draw volume, and syringe units from your vial size, diluent, and target dose — with dosing conventions drawn from the Egrifta prescribing information.
Egrifta SV uses 0.5 mL of diluent per 2 mg vial; research vials are commonly mixed at 1–2 mL.
The standard clinical trial dose is 2,000 mcg (2 mg) once daily.
Draw to
—
units on your syringe
How tesamorelin reconstitution math works
Tesamorelin ships as a freeze-dried (lyophilized) powder that has to be brought into solution before it can be drawn into a syringe. Once it’s mixed with diluent, the peptide is evenly distributed through that liquid, so the strength of your solution depends on just two numbers: how many milligrams are in the vial, and how much liquid you added. If you haven’t worked through this math before, the main Peptide Calculator covers the general reconstitution formula that every peptide, tesamorelin included, follows.
volume to draw (mL) = target dose (mg) ÷ concentration (mg/mL)
syringe units = volume to draw (mL) × syringe scale (100 for U-100, 40 for U-40)
Worked example
A 10 mg research vial mixed with 2 mL of bacteriostatic water gives a concentration of 5 mg/mL. To hit the standard 2 mg (2,000 mcg) clinical dose, you’d draw 0.4 mL — which reads as 40 units on a U-100 insulin syringe. That single vial covers roughly 5 full daily doses before it’s empty.
Tesamorelin dosing by formulation
Tesamorelin dosing looks slightly different depending on which product you’re working with. The FDA-approved Egrifta line has fixed, label-specified doses; research-grade vials are typically dosed to match the original clinical trial protocol. None of these formulations use a titration ramp — dosing starts at the full target amount from the first injection, which sets tesamorelin apart from GLP-1 peptides like semaglutide or tirzepatide that build up gradually.
| Formulation | Vial strength | Diluent volume | Daily dose |
|---|---|---|---|
| Egrifta (original) | 1 mg / vial | Per label, multiple vials pooled | 2 mg once daily |
| Egrifta SV | 2 mg / vial | 0.5 mL sterile water | 1.4 mg (0.35 mL) once daily |
| Egrifta WR | 11.6 mg / vial | 1.3 mL bacteriostatic water | ~1.3 mg once daily |
| Research-grade vial | 2 mg / 5 mg / 10 mg | 1–2 mL (researcher’s choice) | Typically matched to 2 mg/day protocol |
These figures reflect the Egrifta and Egrifta SV prescribing information on file with the FDA. If your research also involves a GLP-1 receptor agonist for fat loss, the retatrutide dosage calculator and tirzepatide dosage calculator use the same underlying formula, adapted to each compound’s own titration schedule.
Mechanism and half-life, briefly
Tesamorelin is a stabilized 44-amino-acid analog of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotroph cells and prompts a pulse of the body’s own growth hormone, which in turn drives IGF-1 production in the liver — it doesn’t supply growth hormone directly the way injectable HGH does. A structural modification protects it from rapid enzymatic breakdown, extending its plasma half-life to roughly 25–40 minutes, long enough to produce a clean GH pulse before it clears. Because the injection is a trigger rather than a depot, once-daily dosing is what the clinical program was built around, and consistent dose timing matters more than precise time-of-day.
The Phase 3 trial program behind the original FDA approval showed tesamorelin reduced visceral abdominal fat by roughly 15–18% over 26 weeks in HIV-associated lipodystrophy, without the glucose-tolerance tradeoff seen with direct growth hormone administration — which is the basis for its FDA indication and why researchers reach for it specifically when visceral fat, rather than fat mass generally, is the variable of interest.
Commonly researched alongside tesamorelin
Tesamorelin is frequently paired with other compounds in body-composition and recovery research, each with its own reconstitution math. Researchers focused on soft-tissue recovery alongside a GHRH protocol often run the numbers through the BPC-157 dosage calculator as a separate line item, since BPC-157 targets a different research question — tissue repair rather than visceral fat or GH pulsatility — and is dosed on its own schedule. For fat-loss protocols that combine a GHRH analog with a GLP-1 agonist, the tirzepatide dosage calculator handles that compound’s weekly titration separately from tesamorelin’s daily dosing, since stacking two mechanisms doesn’t mean stacking their math.
Frequently asked questions
The FDA-labeled dose is 2 mg once daily for original Egrifta, or 1.4 mg once daily for Egrifta SV. Research protocols modeled on the Phase 3 trials generally match the 2 mg/day figure. Enter your specific vial and water volume above for the exact draw.
No. Unlike GLP-1 peptides such as semaglutide, tirzepatide, or retatrutide, tesamorelin’s labeled protocol starts at the full target dose from the first injection — there’s no dose-escalation schedule in the prescribing information.
It depends entirely on your concentration. Egrifta SV’s own math works out to 0.35 mL from a 2 mg vial mixed with 0.5 mL diluent. For a research vial mixed at a different ratio, divide your target dose in mg by your concentration in mg/mL — the calculator above does this instantly.
Both are GHRH-class peptides, but they aren’t dosed the same. Tesamorelin’s clinical dose is 2 mg once daily; sermorelin protocols typically run in the 200–300 mcg range per injection, often dosed at night. They’re not interchangeable milligram-for-milligram, since they differ in receptor affinity and half-life.
No — the syringe type only changes how the same liquid volume is displayed. A U-100 and U-40 insulin syringe both hold 1 mL in the barrel; they just print a different unit scale next to the plunger for that same 1 mL.
No. It performs the arithmetic of concentration and volume based on numbers you enter. It doesn’t evaluate whether a dose, product, or schedule is appropriate for any individual.
Related peptide calculators
References
- DailyMed (National Institutes of Health) — EGRIFTA SV (tesamorelin) Prescribing Information
- U.S. Food & Drug Administration — EGRIFTA (tesamorelin) Original Label
- Falutz J, et al. “Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation.” New England Journal of Medicine, 2007.
- U.S. Food & Drug Administration — Human Drug Compounding